EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy

Cancers - Switzerland
doi 10.3390/cancers12030614
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer

World Journal of Surgical Oncology
SurgeryOncology
2018English

Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Is an Independent Prognostic Marker in Wild-Type KRAS Metastatic Colorectal Cancer After Colorectal Liver Metastasectomy

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- And PIK3CA- Wild-Type Metastatic Colorectal Cancer: The AGITG Randomised Phase II ICECREAM Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2012English

PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With Kras Wild-Type Tumours in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Co-Expression and Prognostic Significance of Putative CSC Markers CD44, CD133, Wild-Type EGFR and EGFRvIII in Metastatic Colorectal Cancer

Oncotarget
Oncology
2019English

A Small Molecule Approach to Degrade RAS With EGFR Repression Is a Potential Therapy for KRAS Mutation-Driven Colorectal Cancer Resistance to Cetuximab

Experimental and Molecular Medicine
BiochemistryMedicineClinical BiochemistryMolecular BiologyMolecular Medicine
2018English

PTEN Loss of Expression Predicts Cetuximab Efficacy in Metastatic Colorectal Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy